The goal of the collaboration is to develop Watson-powered solutions that enable the diabetes community to optimize clinical, research and lifestyle decisions, and address important issues that influence health outcomes, such as social determinants of health.
Diabetes is one of the most common and costly chronic diseases plaguing communities and straining health systems around the world. With 1.4 million people diagnosed in the U.S. each year, there are now more than 29 million Americans living with diabetes and another 86 million with prediabetes. Globally, there are 415 million people living with diabetes. Poorly managed diabetes can lead to serious health complications such as blindness, kidney failure, hypertension, amputation and hypoglycemia. Diabetes and prediabetes cost $322 billion per year, and 1 in 5 health care dollars is spent caring for people with diabetes.
"For more than 75 years, the American Diabetes Association has promoted a data-driven approach to clinical care and disease management because we know it can significantly improve peoples' lives while also reducing health care costs", stated Kevin L. Hagan, CEO of the Association. "By combining the Association's enormous body of valuable data with Watson's cognitive computing capabilities, we will empower people living with diabetes, clinicians and researchers with better data and better insights, which ultimately can lead to better outcomes."
As part of the collaboration, Watson will be trained to understand diabetes data with the goal to identify potential risk factors and create evidence-based, confidence-ranked recommendations for a range of health decisions. Watson will ingest the Association's rich repository of clinical and scientific data, which includes 66 years of data, as well as the Association's aggregated data about self-management, support groups, health/wellness activities and diabetes education. New offerings developed through the collaboration may also draw on data and insights from IBM's Watson Health Cloud and will leverage Watson's capabilities, such as deep Q&A, natural language processing, engagement advisor, similarity analytics, predictive analytics and personality insights.
For providers, the team plans to create a cognitive diabetes database to help inform treatment decisions and care management approaches. Health care providers could tap into personality insights through Watson to tailor their treatment approaches to the needs of an individual. Additionally, providers could identify and address potential risk factors for their patients by comparing an individual to population-level trends of patients with similar characteristics.
For researchers, the Association and IBM Watson Health plan to create a cloud-based data and insights service that enables scientists to apply Watson to the Association's body of clinical and scientific evidence to help them find hidden patterns, potentially identifying the next frontiers for therapeutic discovery. This tool could accelerate significant breakthroughs in some of the most pressing areas of diabetes research.
For patients and caregivers, cognitive tools for people living with diabetes or prediabetes could be developed to provide tailored information and insights, reflecting individual factors such as demographics, disease stage, treatment regimen and behaviours. For example, the collaboration could lead to the creation of a dynamic mobile app that is integrated with Watson Care Manager and may become increasingly personalized as individuals engage with it, effectively getting "smarter" each time it is used.
To kick-start the development of cognitive apps to support people living with diabetes, the Association and IBM are creating a Watson-based innovation challenge for developers. Developers are invited to propose cognitive apps that leverage the Association's rich data repository and Watson insights. The purpose of the challenge is to advance the use of technology to promote health and to ultimately help improve the lives of those living with diabetes or prediabetes. The challenge will be open for submissions this summer, and developers can visit watsonhealth.ibm.com/challengediabetes to learn more.
"As the science of diabetes advances, Big Data presents a tremendous opportunity in diabetes care and prevention. But patients, caregivers and healthcare providers need access to cognitive tools that can help them translate that Big Data into action, and Watson can offer access to timely, personalized insights", stated Kyu Rhee, MD, MPP, chief health officer, IBM Watson Health. "The American Diabetes Association is the ideal partner for IBM to enable this type of developer challenge, given the Association's role establishing clinical care standards worldwide. Our collective goal is to provide the motivation, the tools and the insights to transform clinical care, self-management and accelerate scientific breakthroughs."